Tranzyme prices $10m offering
This article was originally published in Scrip
Tranzyme has priced an offering of 2.6 million shares at $3.85 each, as the company hopes to raise $10 million, with the possibility of a further $1.5 million if the underwriters exercise their overallotment options. The money will be used to develop its oral ghrelin agonist TZP-102 to treat diabetic gastroparesis, for which Phase IIb results are expected by the end of 2012.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.